Navigation Links
IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
Date:3/20/2008

IRVINE, Calif., March 20 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (the Company) (Nasdaq: IDMI) announced today that it has initiated enrollment in a clinical protocol finalized with the U.S. Food and Drug Administration (FDA), which provides mifamurtide (L-MTP-PE) to eligible, high-risk osteosarcoma patients through a compassionate access study.

"This formalized study is in response to the increasing number of requests for compassionate access to L-MTP-PE," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "As we continue to navigate the U.S. and European regulatory processes, we hope this study provides a temporary solution and much needed treatment option for patients with this devastating orphan disease."

Data from 13 patients treated through compassionate access were presented at the 39th Congress of International Society of Pediatric Oncology (SIOP) last year and showed that L-MTP-PE in combination with other therapies is safe, well-tolerated and exhibited signs of disease control. Updated data on the increasing number of patients treated through compassionate access will be presented at the upcoming 21st Annual Meeting of The American Society of Pediatric Hematology/Oncology (ASPHO).

"This compassionate access study is designed to meet an unmet treatment need by providing L-MTP-PE access to high-risk osteosarcoma patients for whom current therapy is not effective or tolerated," said Peter Anderson, M.D., Ph.D., principal investigator and professor of pediatrics, The University of Texas M. D. Anderson Cancer Center in Houston. "Our experience in treating patients with L-MTP-PE in Phase 1, Phase 2, and Phase 3 studies and through compassionate access has been positive to date with good
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
2. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
3. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
8. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
9. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)... , a manufacturer of ergonomically designed laboratory equipment for ... Japan to sell and service the Hitachi ... will utilize its network of sales professionals throughout the ... offer assistance in application use, product benefits and features, options and ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... and director of the Walter and Eliza Hall Institute, ... Australia Leadership and Innovation Award. The award recognises ... as his leadership in promoting the value of health ... Hilton,s scientific career has focussed on the control of ...
... , WEDNESDAY, Nov. 16 (HealthDay News) -- Overall outpatient ... 12 percent between 1999 and 2007, but alarmingly high ... antibiotic-resistant bacteria, researchers warn. The findings were ... Center for Disease Dynamics, Economics & Policy in Washington, ...
... cardiovascular disease who have a genetic variation that diminishes ... standard daily dosage of this medication resulted in improved ... JAMA . The study is being released early online ... Association Scientific Sessions. "Variants in the CYP2C19 ...
... tolerability of the breast cancer drug tamoxifen in male breast ... therapy early because of problems with side effects caused by ... published today in the cancer journal Annals of Oncology ... patients at their institution who had received tamoxifen for an ...
... New York State Senator Jeffrey ... Albert Einstein College of Medicine of Yeshiva University last ... Neurophysiology Laboratory . Several pieces of high-tech diagnostic and ... equipment and specialized video recording devices, were purchased through ...
... By Denise Mann HealthDay Reporter , TUESDAY, Nov. ... at higher risk than brainiacs for later weight gain and added ... had the lowest IQs at about age 18 had higher waist-to-hip ... those IQ tests. It,s known that people with "apple-shaped" bodies, or ...
Cached Medicine News:Health News:Professor Doug Hilton wins Research Australia Award 2Health News:Increasing dosage of clopidogrel for patients with genetic variation improves response to medication 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3Health News:State Sen. Jeff Klein launches Einstein's new lab 2Health News:Study Finds Link Between Low IQ, Large Waistline 2Health News:Study Finds Link Between Low IQ, Large Waistline 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: